BioSpace News Archive

- Phesgo™ Can be Administered in 5 to 8 Minutes Compared with Hours for the Standard Sequential IV Administration of Perjeta® and Herceptin® - - First Subcutaneous Fixed-dose Combination of Two Monoclonal Antibodies Approved Utilizing Halozyme’s ENHANZE® Technology - - Data Showed That 85% of Patients Preferred Phesgo™ Compared to Standard Intravenous Administration -

A new study published today in Blood , the official journal of the American Society of Hematology, sheds light on the mysterious blood clots and inflammation in patients with Novel Coronavirus (COVID-19). The peer-reviewed paper describes a new medicine that may block COVID-19 inflammation being developed by PEEL Therapeutics, a

Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with standard intravenous administration — — Data showed that 85% of patients preferred Phesgo compared to standard intravenous administration —

Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage, regenerative medicine company creating the next generation of differentiated products to improve outcomes in patients undergoing surgery, announced today the launch of its newest OsteGro® family product, OsteGro V,

Accel Clinical Services (ACS), the parent company of Accel Research Sites, is excited to announce its acquisition of the assets of AMPLIFY Clinical.

Medline announced a $120 million annual partnership with The University of Texas System Supply Chain Alliance.

Synergy CHC Corp. (OTCQB: SNYR) (“Synergy” or the “Company”), a consumer health care & beauty company, today reported results for the quarter ended March 31, 2020.

RedHawk Holdings Corp. (OTC: SNDD) (“RedHawk” or the “Company”) a diversified holding company engaged in sales and distribution of medical devices, announced today financial results for the three month period of fiscal year 2020, ended March 31, 2020.

CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $325,000,000 of common shares.

Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for its xMAP® SARS-CoV-2 Multi-Antigen IgG assay